Quality & Regulatory Implications from EU Critical Medicines Act

The draft  CMA regulation was proposed by the European Commission in March 2025 to strengthen the availability, security, and resilience of critical medicines and it represents a significant shift in how manufacturers, Marketing Authorisation Holders (MAHs), quality teams, and supply chain leaders are expected to plan and operate to improve availability and supply of critical medicines within the EU.

Medicine shortages have reached record levels across Europe in recent years, driven by fragmented supply chains, reliance on single‑source manufacturers, geopolitical instability, and the outsourcing of critical production steps.

The CMA creates a framework for strategic projects, adapted public and collaborative procurement, and international partnerships to foster resilient, EU‑anchored but globally diversified supply chains. It also hard‑wires new obligations around information‑sharing, supply‑chain transparency and stockpiling and mandating more robust risk-mitigation strategies.

When: timing and legislative trajectory

The Commission proposal was tabled in March 2025, with Council and European Parliament negotiations expected through 2025–2026. Law‑firm and policy analyses broadly anticipate political agreement in 2026, with phased implementation of obligations over 2026–2027 once the regulation is adopted.

In parallel, key building blocks are already in place: Regulation (EU) 2022/123 has applied since March 2022, and EMA’s first Union List of Critical Medicines was published in December 2023. Companies therefore cannot wait for the final text; they must treat the CMA as an imminent, shaping force for GMP, supply, regulatory and quality strategies in the 2026–2030 window.

New transparency and reporting duties for industry

Analyses of the CMA proposal highlight that pharmaceutical companies will face enhanced transparency requirements, including:

• Regular reporting on production capacity, manufacturing locations and key suppliers for critical products.
• Notification of supply disruptions, reliance on single sites or single‑source API suppliers, and other vulnerabilities requested in Commission or EMA‑led assessments.
• Obligations to respond to information requests for both critical medicines and MPCIs, expanding beyond traditional pharmacovigilance or variation‑driven reporting.

Stockpiling, procurement and industrial measures

The CMA envisages that Member States establish mandatory or coordinated stockpiling schemes for critical medicines and may extend these to drugs of common interest. It explicitly encourages national programmes “to improve security of supply,” including adapted public‑procurement procedures that “value security, quality and EU production rather than price alone.”

Key tools include:

• Strategic projects for critical medicines or their ingredients, benefiting from easier access to funding and fast‑tracked permitting.
• Public procurement mechanisms that reward resilient supply (multi‑site, EU‑based, dual‑source) and not only lowest price.
• Collaborative procurement procedures allowing groups of Member States to aggregate demand and jointly procure critical medicines and MPCIs.
• International partnerships with “like‑minded” countries to diversify global supply while reducing over‑reliance on single regions. europa​

Where and who: geography, product scope and stakeholders

The Act will apply across all EU Member States, building on common lists and EU‑level coordination but implemented through both Union‑wide mechanisms (e.g. strategic projects, collaborative procurement) and national programmes (e.g. stockpiles, procurement criteria, state‑aid measures).

Key affected stakeholders include:

• Pharmaceutical manufacturers and MAHs for both originator and generic medicines in critical categories.
• API and intermediate suppliers whose concentration risk will be scrutinised in vulnerability assessments.
• National health authorities and procurement bodies, which must recalibrate tenders away from price‑only criteria towards resilience and EU production.
• EU bodies (coordinating lists, forecasts, funding and crisis responses.

Implications for supply chain, dual sourcing and regulatory surveillance

For quality and regulatory teams, the CMA transforms shortages from a predominantly pharmacovigilance‑adjacent reporting duty into a strategic compliance and supply‑chain design obligation.

Key themes include:

• Supply chain redesign: Companies will need to map critical products against EU lists, identify single points of failure, and develop de‑risked architectures (multi‑site, multi‑supplier, nearshored API) that can withstand EMA and Commission scrutiny.
• Dual sourcing as default: Reliance on a single API site or one key intermediate supplier for a ULCM product will become increasingly hard to justify, especially in tenders where resilience is an award criterion.
• Regulatory surveillance: Continuous tracking of list updates, guidance from EMA, national implementation and procurement reforms will be essential for MAHs seeking to maintain market access and secure contracts

Strategy ready for the CMA?

How MIAS can support your strategy:

1. Regulatory and policy horizon scanning
   • Continuous monitoring and interpretation of CMA negotiations, EMA/MSSG guidance, updates to the Union list and national implementation acts.
   • Early‑warning dashboards for quality and regulatory leaders, highlighting where new obligations on information‑sharing, stockpiling or procurement will bite for specific portfolios.
2. Critical‑product and supply‑chain mapping
   • Structured assessment of client portfolios against ULCM and MPCI criteria, integrated with QP‑driven reviews of GMP, API sourcing and release/testing networks.
   • Development of dual‑sourcing and multi‑site strategies, including regulatory roadmaps for technology transfer, comparability and lifecycle variation planning.
3. Shortage and transparency governance
   • Design of end‑to‑end processes for shortage detection, internal escalation and timely reporting through EMA and national channels, leveraging the i‑SPOC and SPOC network architecture.
   • Data stewardship and systems alignment so that production‑capacity, stock and supplier‑dependency metrics are reliable enough to support Commission or EMA information requests.
4. Tender, stockpiling and strategic‑project support
   • Advice on aligning CMC, supply and QMS narratives with new procurement criteria that reward security of supply, quality and EU production.
   • Support in building business cases and documentation for designation as a strategic project, and in structuring partnerships with EU manufacturers or “like‑minded” third countries.

By combining deep EMA/HPRA regulatory expertise with practical manufacturing and supply‑chain understanding, MIAS can help clients move from reactive shortage compliance to proactive critical‑medicines strategy—turning the Critical Medicines Act from a compliance risk into a competitive differentiator in the EU market.